Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 17, 2026International Archives of Allergy and Immunology

Efficacy and Safety of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RKRoy KhalafATAlexandre Ton ThatNTNatacha Tardio

Discussion

Loading...

Member takes

Overview

Systematic review evaluates dupilumab effectiveness in symptom relief for eosinophilic esophagitis patients, implying a viable treatment option.

Key Points

  • This review assesses the efficacy and safety of dupilumab in treating eosinophilic esophagitis across various age groups.
  • Systematic review and meta-analysis of studies from MEDLINE and Embase up to June 30, 2025.
  • Inclusion of randomized controlled trials, cohort studies, and case reports reporting dupilumab use in eosinophilic esophagitis.
  • Data extraction on histologic outcomes, symptom improvement, and adverse events, assessed in duplicate.
  • Histologic remission occurred in 60%-84% of dupilumab-treated patients versus <10% of placebo in randomized controlled trials.
  • Pediatric cohorts exhibited strong responses, with remission rates up to 90%.
  • Meta-analysis revealed a pooled histologic remission rate of 75.5% (95% CI, 67.4–82.1%) and a symptom improvement rate of 84.1% (95% CI, 77.8–88.9%).

Cite This Study

Khalaf et al. (2026) studied this question.

synapsesocial.com/papers/6a59c7cca58755010b4728b7https://doi.org/10.1159/000553602
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dupilumab for adult and adolescent patients with primary eosinophilic colitis2025
  2. 2Dupilumab Administration in the Patient with Severe Eosinophilic Esophagitis Combined with T2-Associated Diseases: Case Study2025
  3. 3Monoclonal Antibodies for Eosinophilic Esophagitis and Gastritis2025
  4. 4Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness2025 · 14 citations
  5. 5Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China2025 · 3 citations